Stock BIIB BIOGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
194.1 USD -0.14% Intraday chart for Biogen Inc. -1.37% -24.99%
Apr. 19 Needham Adjusts Price Target on Biogen to $294 From $300 MT
Apr. 19 BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept MT

Business Summary

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:

- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;

- royalties (17,2%) ;

- other (9,1%): primarily revenues from partnership agreements.

Number of employees: 7,570

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Therapies
100.0 %
10,173 100.0 % 9,836 100.0 % -3.32%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
55.2 %
5,532 54.4 % 5,434 55.2 % -1.77%
Europe
21.8 %
2,413 23.7 % 2,140 21.8 % -11.34%
Germany
8.8 %
926 9.1 % 868 8.8 % -6.28%
Asia
8.8 %
720 7.1 % 863 8.8 % +19.97%
Other
5.4 %
583 5.7 % 531 5.4 % -8.87%

Managers

Managers TitleAgeSince
Christopher Viehbacher CEO
 Chief Executive Officer 64 22-11-13
Michael McDonnell DFI
 Director of Finance/CFO 60 20-08-14
Nicole Murphy COO
 Chief Operating Officer - 14-12-31
Jane Grogan CTO
 Chief Tech/Sci/R&D Officer 57 23-10-01
Chuck Triano IRC
 Investor Relations Contact - 23-04-09
Michael Hencke IRO
 Public Communications Contact - 12-06-30
Michael Dambach TRE
 Treasurer 57 06-12-31
Wendell C. Taylor SEC
 Corporate Secretary - -
Robert Kilo PRN
 Corporate Officer/Principal - -
Rachid Izzar PRN
 Corporate Officer/Principal - 20-12-31

Members of the board

Members of the board TitleAgeSince
Stephen Sherwin BRD
 Director/Board Member 75 09-12-31
William Hawkins BRD
 Director/Board Member 70 19-06-18
Caroline Dorsa CHM
 Chairman 64 10-01-02
Eric Rowinsky BRD
 Director/Board Member 67 10-03-19
Christopher Viehbacher CEO
 Chief Executive Officer 64 22-11-13
Maria Freire BRD
 Director/Board Member 69 21-06-01
Monish Patolawala BRD
 Director/Board Member 54 Dec. 31
Jesus B. Mantas BRD
 Director/Board Member 55 19-06-18
Susan Langer BRD
 Director/Board Member - 23-06-25

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 169,160,798 144,360,393 ( 85.34 %) 23,800,000 ( 14.07 %) 85.34 %

Shareholders

NameEquities%Valuation
PRIMECAP Management Co.
11.19 %
16,264,481 11.19 % 3 507 M $
The Vanguard Group, Inc.
9.990 %
14,521,342 9.990 % 3 131 M $
Vanguard Fiduciary Trust Co.
9.911 %
14,407,330 9.911 % 3 107 M $
BlackRock Advisors LLC
6.961 %
10,118,832 6.961 % 2 182 M $
STATE STREET CORPORATION
4.778 %
6,945,665 4.778 % 1 498 M $
T. Rowe Price Investment Management, Inc.
3.686 %
5,357,326 3.686 % 1 155 M $
Wellington Management Co. LLP
3.663 %
5,324,396 3.663 % 1 148 M $
JPMorgan Investment Management, Inc.
3.443 %
5,004,504 3.443 % 1 079 M $
BlackRock Life Ltd.
2.649 %
3,850,737 2.649 % 830 M $
Geode Capital Management LLC
2.277 %
3,309,317 2.277 % 714 M $
NameEquities%Valuation
BB Gestão de Recursos DTVM SA
0.000187 %
1,630 0.000187 % 58 498 $
Bram Bradesco Asset Management S/A DTVM
0.000003 %
30 0.000003 % 1 077 $

Holdings

NameEquities%Valuation
DENALI THERAPEUTICS INC.
9.16%
 12,751,365 9.16% 261,658,010 $
SAGE THERAPEUTICS, INC.
10.38%
 6,241,473 10.38% 116,965,204 $
SANGAMO THERAPEUTICS, INC.
7.19%
 14,652,466 7.19% 9,817,152 $

Company contact information

Biogen, Inc.

225 Binney Street

02142, Cambridge

+617 679 2000

http://www.biogen.com
address Biogen Inc.(BIIB)

Group companies

NameCategory and Sector
Biogen MA, Inc.
Logo Biogen MA, Inc.

Biogen MA, Inc.

BiotechnologyHealth Technology

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Biotechnology
Biogen International GmbH
Logo Biogen International GmbH

Biogen International GmbH

Pharmaceuticals: MajorHealth Technology

Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland.

Pharmaceuticals: Major

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Biogen Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
194.1 USD
Average target price
290.8 USD
Spread / Average Target
+49.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
BIOGEN INC. Stock Biogen Inc.
-24.99% 28.22B
CSL LIMITED Stock CSL Limited
-2.68% 85.68B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+5.53% 41.4B
UCB Stock UCB
+54.63% 24.64B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-7.19% 16.98B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-34.20% 13.29B
INCYTE CORPORATION Stock Incyte Corporation
-17.31% 11.66B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.43% 11.65B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-1.57% 8.18B
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
+4.08% 7.78B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. Company Biogen Inc.